Review
doi: 10.1038/ni1443.
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Affiliations
- PMID: 17304234
- DOI: 10.1038/ni1443
Item in Clipboard
Review
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Nat Immunol.
2007 Mar.
Abstract
The programmed cell death 1 (PD-1) surface receptor binds to two ligands, PD-L1 and PD-L2. Studies have shown that PD-1-PD-L interactions control the induction and maintenance of peripheral T cell tolerance and indicate a previously unknown function for PD-L1 on nonhematopoietic cells in protecting tissues from autoimmune attack. PD-1 and its ligands have also been exploited by a variety of microorganisms to attenuate antimicrobial immunity and facilitate chronic infection. Here we examine the functions of PD-1 and its ligands in regulating antimicrobial and self-reactive T cell responses and discuss the therapeutic potential of manipulating this pathway.
Similar articles
-
The role of the PD-1 pathway in autoimmunity and peripheral tolerance.Ann N Y Acad Sci. 2011 Jan;1217:45-59. doi: 10.1111/j.1749-6632.2010.05919.x. Ann N Y Acad Sci. 2011. PMID: 21276005 Review.
-
PD-L2 is a second ligand for PD-1 and inhibits T cell activation.Nat Immunol. 2001 Mar;2(3):261-8. doi: 10.1038/85330. Nat Immunol. 2001. PMID: 11224527
-
PD-1 and PD-1 ligands: from discovery to clinical application.Int Immunol. 2007 Jul;19(7):813-24. doi: 10.1093/intimm/dxm057. Epub 2007 Jul 2. Int Immunol. 2007. PMID: 17606980 Review.
-
Expression of PD-1, PD-L1, and PD-L2 in the liver in autoimmune liver diseases.Am J Gastroenterol. 2007 Feb;102(2):302-12. doi: 10.1111/j.1572-0241.2006.00948.x. Am J Gastroenterol. 2007. PMID: 17311651
-
Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses.Transplantation. 2007 Mar 27;83(6):774-82. doi: 10.1097/01.tp.0000256293.90270.e8. Transplantation. 2007. PMID: 17414712
Cited by
-
The implication of _targeting PD-1:PD-L1 pathway in treating sepsis through immunostimulatory and anti-inflammatory pathways.Front Immunol. 2023 Dec 13;14:1323797. doi: 10.3389/fimmu.2023.1323797. eCollection 2023. Front Immunol. 2023. PMID: 38193090 Free PMC article. Review.
-
Evaluation of Chelator-to-Antibody Ratio on Development of 89Zr-iPET Tracer for Imaging of PD-L1 Expression on Tumor.Int J Mol Sci. 2023 Dec 5;24(24):17132. doi: 10.3390/ijms242417132. Int J Mol Sci. 2023. PMID: 38138961 Free PMC article.
-
Inhibitor of PD-1/PD-L1: a new approach may be beneficial for the treatment of idiopathic pulmonary fibrosis.J Transl Med. 2024 Jan 23;22(1):95. doi: 10.1186/s12967-024-04884-7. J Transl Med. 2024. PMID: 38263193 Free PMC article. Review.
-
The Role of Type I IFNs in Influenza: Antiviral Superheroes or Immunopathogenic Villains?J Innate Immun. 2020;12(6):437-447. doi: 10.1159/000508379. Epub 2020 Jun 19. J Innate Immun. 2020. PMID: 32564033 Free PMC article. Review.
-
Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients.Clin Cancer Res. 2016 Dec 15;22(24):6278-6289. doi: 10.1158/1078-0432.CCR-15-2443. Epub 2016 Jun 1. Clin Cancer Res. 2016. PMID: 27252415 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
